Robust recovery in non-COVID-19 business ensures a beat in Q1
04/05/21 -"Benefiting from strong demand for sample technology solutions and the QuantiFERON-TB test, Qiagen’s non-COVID-19 business was back in the black in Q1 21. Expectedly, COVID-19 products witnessed a ..."
Pages
62
Language
English
Published on
04/05/21
You may also be interested by these reports :
15/12/25
We have revised our estimates upwards to account for enhanced profitability, despite the effects of tariffs and foreign exchange headwinds. This ...
11/12/25
CZM reported its full-year FY2024-25 results, aligning with guidance. Sales growth was supported by contributions from both segments, though ...
09/12/25
In addition to our estimates being revised lower, we have applied a 10% discount to peer-based valuation metrics to reflect the delayed recovery in ...
05/12/25
In addition to revising our estimates downwards to address near-term challenges, we have also injected a 20% discount into peer-based valuation ...